Ekterly Tablet
Product Images NDC 82928-300

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ekterly (NDC 82928-300). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kalvista Pharmaceuticals Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tablet Logo (01 Tablet Logo)

EKTERLY 300 mg oral tablet blister pack. The packaging shows tablets arranged in a single row within a clear plastic blister, backed by foil. Labeling includes the proprietary name EKTERLY and drug strength 300 mg. Manufacturer identified as KalVista Pharmaceuticals Ltd.*

FDA Label Image

Structure (02 Structure)

Chemical structure diagram of sebetralstat, the active ingredient in EKTERLY 300 mg oral tablets by KalVista Pharmaceuticals Ltd.*

FDA Label Image

Figure 1 (03 Figure 1)

A cumulative percent graph showing patients reaching beginning of symptom relief within 12 hours after administration. The x-axis represents time from first administration in hours, and the y-axis shows cumulative percent of patients. Two lines compare EKTERLY 600 mg (solid line) and placebo (dashed line), with EKTERLY showing a higher cumulative response over time.*

FDA Label Image

Figure 2 (04 Figure 2)

A graph showing the cumulative percentage of patients reaching the beginning of reduction in severity within 12 hours after first administration, comparing EKTERLY 600 mg and placebo. The x-axis represents time in hours, and the y-axis shows cumulative percent. EKTERLY shows a higher and faster cumulative response than placebo over the 12-hour period.*

FDA Label Image

Figure 3 (05 Figure 3)

A line graph comparing the cumulative percent of patients with attack resolution within 24 hours between EKTERLY 600 mg and placebo. The x-axis shows time from first administration (0 to 24 hours), and the y-axis shows cumulative percent. The EKTERLY group (solid line) shows a higher cumulative percent over time than the placebo group (dashed line), which exhibits a lower and slower increase.*

FDA Label Image

Image Description (06 Carton 4 Blisters)

Packaging label for EKTERLY (sebetralstat) tablets 300 mg by KalVista Pharmaceuticals Ltd. The label features the brand and generic names, strength, and dosage form. It indicates four blister packages each containing a single tablet. The design uses a blue and white background with an orange wave, includes the National Drug Code (NDC) 82928-300-04, and notes the product is Rx only.*

FDA Label Image

Image Description (07 Carton Inside)

EKTERLY (sebetralstat) tablets 300 mg carton label for oral use, labeled for prescription only. The packaging design features a blue and orange color scheme with instructions for tablet removal depicted in three illustrated steps. The label shows the KalVista Pharmaceuticals Ltd logo and includes a QR code.*

FDA Label Image

Image Description (08 Blister Walled)

Packaging label for Ekterly (sebetralstat) tablets 300 mg, a prescription oral tablet by KalVista Pharmaceuticals. The label shows the proprietary name, generic name, strength, and dosage form. The package design includes instructions with illustrations on how to open the child-resistant package, which contains 1 film-coated tablet. The color scheme is primarily dark blue with orange and white accents.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.